Gossamer Bio (GOSS) has just closed out FY 2025 with fourth quarter revenue of about US$13.8 million and a basic EPS loss of US$0.21, alongside a trailing twelve month EPS loss of US$0.75 on revenue of US$48.5 million. This sets a clear snapshot of where the business stands heading into 2026. Over recent quarters the company has seen revenue move from US$9.4 million in Q4 2024 through US$9.9 million, US$11.5 million and US$13.3 million to US$13.8 million in Q4 2025, while quarterly EPS losses have ranged between US$0.14 and US$0.21. Investor attention remains on how quickly margins can tighten from here.

See our full analysis for Gossamer Bio.

With the latest numbers on the table, the next step is to see how this earnings profile lines up with the widely held growth and profitability narratives around Gossamer Bio, and where those stories start to diverge.

US$170 million annual loss frames the current risk

• On a trailing twelve month basis, Gossamer Bio reported net loss of about US$170.4 million on US$48.5 million of revenue, which means expenses substantially exceed revenue at this stage.
• Critics highlight that ongoing R&D and clinical spend could keep pressure on results, and the reported cash runway of under one year and negative shareholders’ equity support that cautious view:
  • The trailing twelve month loss of about US$170.4 million is much larger than any single quarter loss, so cash needs to cover a heavy annual burn, not just one period.
  • With the company still pre profit and reliant on funding, the bearish concern about dilution risk and sensitivity to tighter capital markets is directly tied to this loss profile.

Skeptics focused on funding risk point to this earnings profile as a clear example of why they stay cautious on the stock. 🐻 Gossamer Bio Bear Case

Revenue rising, but losses widen alongside growth

• Quarterly revenue moved from US$9.4 million in Q4 2024 to US$13.8 million in Q4 2025, while quarterly net loss (excluding extra items) widened from about US$33.0 million to US$47.2 million over the same points.
• Supporters of the bullish view argue that heavier losses today can set up future payoff through seralutinib and other pipeline assets, but these figures show the trade off clearly:
  • The trailing twelve month revenue of about US$48.5 million sits against revenue growth forecasts of 46.3% a year, so the bullish thesis leans heavily on future scaling from a relatively small base.
  • Forecast earnings growth of about 63.7% a year and an expectation of profitability within three years contrast with the current annual loss of about US$170.4 million, which is why bulls focus on the potential impact of successful Phase III trials and commercialization.

Bulls point to these higher recent revenues as the starting point for the growth story they see playing out if trials and approvals go to plan. 🐂 Gossamer Bio Bull Case

Low P/S multiple versus sector and DCF fair value

• At a share price of about US$0.43, Gossamer Bio is trading on a P/S of roughly 2.1x compared with 11.5x for the US biotech industry and 30.7x for peers, while a DCF fair value estimate of about US$12.22 per share sits well above the current price.
• Consensus narrative notes that growth forecasts and pipeline potential help explain why some investors focus on valuation gaps, but the wide spread between price and model values also reflects balance sheet and execution risks:
  • The analyst target level of US$3.69, when set against the current US$0.43 share price, implies a large gap that investors would weigh against factors like negative equity and short cash runway.
  • The combination of relatively low P/S and a large difference between price, analyst target and DCF fair value means the numbers can support both a value oriented angle and the bearish view that the market is heavily discounting execution and funding risk.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Gossamer Bio on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both the risks and the upside laid out, it makes sense to move quickly and test the numbers yourself. To weigh up the potential trade off between those concerns and opportunities, take a closer look at the 3 key rewards and 3 important warning signs

See What Else Is Out There

Gossamer Bio's heavy annual loss, short cash runway and negative shareholders' equity highlight meaningful funding and balance sheet risk alongside its current growth story.

If you want ideas with sturdier finances and less funding pressure, now is a good time to check companies in the solid balance sheet and fundamentals stocks screener (40 results) that aim to pair resilience with opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.